Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-19 | Dr. Alexandria ForbesCEO, President & Director | -62,00k | 568,54k | Automatic Disposition | 9,17 | 1,39M | -4,28% |
| 2026-01-07 | Dr. Robert K. ZeldinChief Medical Officer | -7,81k | 60,40k | Sale to Issuer | 7,73 | 146,20k | -5,07% |
| 2026-04-21 | Mr. Richard Brian GirouxCOO & CFO | -56,00k | 572,32k | Automatic Disposition | 10,22 | 1,06M | -5,01% |
| 2026-04-07 | Dr. Stuart NaylorChief Scientific Officer of Ophthalmology | -27,66k | 258,91k | Automatic Disposition | 9,36 | 668,51k | -3,97% |
| 2026-03-24 | Dr. Alexandria ForbesCEO, President & Director | -62,00k | 459,42k | Automatic Disposition | 7,41 | 1,45M | -4,10% |
| 2026-02-21 | Dr. Robert K. ZeldinChief Medical Officer | 4,55k | 0,00 | Derivative Exercise and Retained Stock | - | 172,89k | 2,70% |
| 2026-02-21 | Dr. Robert K. ZeldinChief Medical Officer | -2,95k | 21,99k | Derivative Exercise and Sale | 7,45 | 172,89k | - |
| 2026-02-21 | Mr. Robert J. WollinGeneral Counsel & Secretary | 5,30k | 0,00 | Derivative Exercise and Retained Stock | - | 57,38k | 10,18% |
| 2026-02-21 | Mr. Robert J. WollinGeneral Counsel & Secretary | -5,95k | 44,32k | Derivative Exercise and Sale | 7,45 | 57,38k | - |
| 2026-02-21 | Dr. Stuart NaylorChief Scientific Officer of Ophthalmology | 13,25k | 0,00 | Derivative Exercise and Retained Stock | - | 696,17k | 1,94% |
| 2026-02-21 | Dr. Stuart NaylorChief Scientific Officer of Ophthalmology | -11,75k | 87,54k | Derivative Exercise and Sale | 7,45 | 696,17k | - |
| 2026-02-21 | Mr. Richard Brian GirouxCOO & CFO | 28,27k | 0,00 | Derivative Exercise and Retained Stock | - | 1,12M | 2,60% |
| 2026-02-21 | Mr. Richard Brian GirouxCOO & CFO | -31,73k | 236,36k | Derivative Exercise and Sale | 7,45 | 1,12M | - |
| 2026-02-21 | Dr. Alexandria ForbesCEO, President & Director | 29,45k | 0,00 | Derivative Exercise and Retained Stock | - | 1,51M | 1,99% |
| 2026-02-21 | Dr. Alexandria ForbesCEO, President & Director | -33,05k | 246,21k | Derivative Exercise and Sale | 7,45 | 1,51M | - |
| 2026-01-17 | Dr. Robert K. ZeldinChief Medical Officer | 21,05k | 0,00 | Derivative Exercise and Retained Stock | - | 168,34k | 14,29% |
| 2026-01-17 | Dr. Robert K. ZeldinChief Medical Officer | -13,95k | 103,52k | Derivative Exercise and Sale | 7,42 | 168,34k | - |
| 2026-01-17 | Mr. Robert J. WollinGeneral Counsel & Secretary | 22,79k | 0,00 | Derivative Exercise and Retained Stock | - | 52,08k | 77,84% |
| 2026-01-17 | Mr. Robert J. WollinGeneral Counsel & Secretary | -27,21k | 201,87k | Derivative Exercise and Sale | 7,42 | 52,08k | - |
| 2026-01-17 | Dr. Stuart NaylorChief Scientific Officer of Ophthalmology | 39,75k | 0,00 | Derivative Exercise and Retained Stock | - | 682,92k | 6,18% |
| 2026-01-17 | Dr. Stuart NaylorChief Scientific Officer of Ophthalmology | -35,25k | 261,56k | Derivative Exercise and Sale | 7,42 | 682,92k | - |
| 2026-01-17 | Mr. Richard Brian GirouxCOO & CFO | 146,08k | 0,00 | Derivative Exercise and Retained Stock | - | 1,09M | 15,49% |
| 2026-01-17 | Mr. Richard Brian GirouxCOO & CFO | -163,92k | 1,22M | Derivative Exercise and Sale | 7,42 | 1,09M | - |
| 2026-01-17 | Dr. Alexandria ForbesCEO, President & Director | 146,08k | 0,00 | Derivative Exercise and Retained Stock | - | 1,48M | 10,93% |
| 2026-01-17 | Dr. Alexandria ForbesCEO, President & Director | -163,92k | 1,22M | Derivative Exercise and Sale | 7,42 | 1,48M | - |
| 2026-01-07 | Dr. Robert K. ZeldinChief Medical Officer | 17,50k | 0,00 | Derivative Exercise and Retained Stock | - | 146,20k | 13,60% |
| 2026-01-07 | Mr. Robert J. WollinGeneral Counsel & Secretary | 3,14k | 0,00 | Derivative Exercise and Retained Stock | - | 29,28k | 11,99% |
| 2026-01-07 | Mr. Robert J. WollinGeneral Counsel & Secretary | -4,36k | 33,73k | Derivative Exercise and Sale | 7,73 | 29,28k | - |
| 2026-01-07 | Dr. Stuart NaylorChief Scientific Officer of Ophthalmology | 19,88k | 0,00 | Derivative Exercise and Retained Stock | - | 643,17k | 3,19% |
| 2026-01-07 | Dr. Stuart NaylorChief Scientific Officer of Ophthalmology | -17,63k | 136,24k | Derivative Exercise and Sale | 7,73 | 643,17k | - |
| 2026-01-07 | Mr. Richard Brian GirouxCOO & CFO | 23,68k | 0,00 | Derivative Exercise and Retained Stock | - | 943,32k | 2,57% |
| 2026-01-07 | Mr. Richard Brian GirouxCOO & CFO | -28,82k | 222,79k | Derivative Exercise and Sale | 7,73 | 943,32k | - |
| 2026-01-07 | Dr. Alexandria ForbesCEO, President & Director | 28,43k | 0,00 | Derivative Exercise and Retained Stock | - | 1,34M | 2,17% |
| 2026-01-07 | Dr. Alexandria ForbesCEO, President & Director | -34,07k | 263,39k | Derivative Exercise and Sale | 7,73 | 1,34M | - |
| 2025-12-31 | Perceptive Advisors LLCUnternehmen | -2,30M | 18,19M | Sale to Issuer | 7,91 | 10,23M | -18,35% |
| 2025-12-23 | Dr. Alexandria ForbesCEO, President & Director | -6,25k | 0,00 | Other Disposition | - | 1,31M | -0,48% |
| 2025-11-20 | Mr. Robert J. WollinGeneral Counsel & Secretary | -5,00k | 0,00 | Other Disposition | - | 26,15k | -16,05% |
| 2025-10-21 | Mr. Richard Brian GirouxCOO & CFO | -24,00k | 212,88k | Automatic Disposition | 8,87 | 919,65k | -2,54% |
| 2025-10-07 | Dr. Alexandria ForbesCEO, President & Director | -47,50k | 398,53k | Automatic Disposition | 8,39 | 1,31M | -3,49% |
| 2025-07-22 | Mr. Richard Brian GirouxCOO & CFO | -24,00k | 204,48k | Automatic Disposition | 8,52 | 943,65k | -2,48% |
| 2025-07-08 | Dr. Alexandria ForbesCEO, President & Director | -47,50k | 378,58k | Automatic Disposition | 7,97 | 1,36M | -3,37% |
| 2025-06-30 | Mr. Richard Brian GirouxCOO & CFO | -5,00k | 0,00 | Other Disposition | - | 967,65k | -0,51% |
| 2025-06-06 | Dr. Keith Reginald HarrisIndependent Chairman of the Board | 75,00k | 0,00 | Derivative Exercise and Retained Stock | - | 125,00k | 150,00% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
